Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study.

Intest Res · 2018 · PMC5934598 · PMID 29743838

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Concerning the main UC categories (classification by disease course, extent of disease, UC-DAI score at baseline), the Multimatrix-4.8 group showed a trend towards greater improvement in the UC-DAI score than the Time-2.25 group in all subgroups ( Table 5 ). 3.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.